ORIGINAL ARTICLE

Structural robustness of the gut mucosal microbiota is associated with Crohn’s disease remission after surgery

S Mondot,1,2 P Lepage,1,2 P Seksik,4 M Allez,5 X Tréton,6 Y Bouhnik,6 J F Colombel,7 M Leclerc,1,2 P Pochart,8,9 J Doré,1,2 P Marteau,10 the GETAID11

ABSTRACT

Objectives Preventing postoperative recurrence after ileocolonic resection (ICR) for Crohn’s disease (CD) is challenging. Defining the disturbances of the microbial composition and community structure after ICR and their link with early disease recurrence is crucial.

Design Microbiota composition (fingerprinting and 16S rDNA sequencing) and community structure (correlation networks of bacterial species) were assessed from ileal mucosa sampled in 20 patients undergoing ICR and 6 months later during endoscopy from above (neoterminal ileum) and below (subanastomotic colon) the surgical anastomosis.

Results ICR had a dramatic effect on gut microbial ecosystem. At surgery, CD mucosa harboured a dysbiotic microbiota with high proportions of α/β Proteobacteria and Bacilli. Six months later, half of the patients had recurrent lesions at ileocolonoscopy and presented higher numbers of Lachnospiraceae. Recurrence of endoscopic lesions was associated with enrichment in Enterococcus durans while patients in remission undergoing ICR and 6 months later during endoscopy from above (neoterminal ileum) and below (subanastomotic colon) the surgical anastomosis.

Conclusions ICR modifies the gut microbiome. Remission after 6 months was associated with homogeneous bacterial distribution around the anastomosis. Community structure and bacterial networks highlight target species, including Faecalibacterium prausnitzii and Ruminococcus gravis, which may allow precise modulations of the overall microbial ecosystem towards remission pattern.

INTRODUCTION

Crohn’s disease (CD) is a chronic inflammatory disease of the intestine with an increasing incidence worldwide.1 It is a multifactorial disease where host genetic impairments and environmental triggers lead to the onset and maintenance of inappropriate host immune responses at the gut mucosa interface. More than 70 genetic loci have been linked to CD phenotype transmission,2 and interestingly, most of them involve several key host defences (NOD2, IL23R, ATG16L1, FUT2). Environmental factors, especially smoking habits, are also involved. Results obtained from experimental mouse models3 have shed light on different mechanisms emphasising the involvement of the gut mucosa. The use of immunologic–microbiologic interactions sustain numerous physiological functions such as the maturation of host intestinal/immune cells (lymphoid tissue, Paneth cells) and the settlement of a commensal microbiota. The use of immunologically impaired animal models has emphasised the importance of this relationship. For instance, TRUC mice (T-bet+/− RAG2+/− UC model) are able to shape an aberrant microbiota leading to

Significance of this study

What is already known on this subject?

▸ Recurrence of Crohn’s disease (CD) after ileocolonic resection (ICR) is frequent.
▸ Luminal flux and gut microbiota are involved in this setting.

What are the new findings?

▸ ICR for CD strongly modifies the gut mucosal microbiota.
▸ Spatial homogeneity in bacterial composition around the anastomosis is associated with maintenance of endoscopic remission.
▸ Microbial community structure and bacterial species assemblages are cohesive during remission while a loose structure, together with a cluster of bacteria from the Proteobacteria phylum, is associated with endoscopic recurrence.

How might it impact on clinical practice in the foreseeable future?

▸ Bacterial recolonisation following ICR might pave the way towards remission or recurrence.
▸ Community structure and bacterial networks highlight target species that may allow precise modulations of the overall microbial ecosystem towards remission pattern.
Components of the faecal stream may play a role. Corticosteroids, thiopurines and monoclonal antibodies against tumour necrosis factor-α are efficient to modulate inflammatory activity, but surgery is still frequently required. Strikingly, severe inflammatory lesions recur in the neoterminal ileum in the months following surgery in more than half of the patients operated on to remove the inflamed ileum. The crucial link between gut microbiota and CD recurrence was first suspected in this context two decades ago. In five patients with CD who had undergone resection with a diverting loop ileostomy proximal to an ileocolonic anastomosis, lesions occurred in the neoterminal ileum only once the bowel continuity was restored, which suggested that the microbiota and/or other components of the faecal stream may play a role.

The importance of the human gut microbiome in health and disease has been recognised for decades. In CD, it seems of great interest to investigate the mucosal microbiota that differs from faecal samples as it is in close contact to the disease process. In this study, we aimed at (i) assessing the impact of the ileocolonic resection (ICR) on the mucosa-associated microbiota, (ii) observing whether alterations differed between patients in remission or in recurrence after ICR, (iii) highlighting bacterial biomarkers of early recurrence of inflammatory lesions, and finally, (iv) deciphering bacterial community structure at the mucosal level in patients.

Microbial profiling and in-depth sequencing techniques were applied to analyse the gut microbiota. Since ecological constraints in the gut (chemical, immunological or trophic) are crucial in shaping the microbiota assembly and necessary for the development of a structured and functional ecosystem, we analysed the microbiota for its composition, diversity and structure in patients suffering from CD before and 6 months following operation to track out any change in microbiota composition and decipher the microbial recolonisation process following ICR.

**PATIENTS AND METHODS**

**Patients and samples**

Twenty patients with active CD were included in this study. They were part of a double-blind, randomised, placebo-controlled, 6-month clinical study, aiming at assessing the efficacy of the probiotic strain *Lactobacillus johnsonii* LA1 to decrease the endoscopic recurrence rate 6 months after surgery. CD was diagnosed on the basis of standard clinical, radiographic, endoscopic and pathological criteria. The patients had to be addressed to clinical centres for ileal or ICR. Patients who received antibiotics during the previous three months or receiving antibiotics for >2 weeks after surgery were not eligible. Other exclusion criteria included (i) total or subtotal colectomy, intestinal bypass or stricturoplasty, stomy, carcinoma resection, or abscess drainage; (ii) treatment with aminosilicates or immunosuppressants >3 weeks following surgery; (iii) any other disease or condition that might interfere with the study assessments (as judged by the investigator); and (iv) child-bearing potential in women not using effective contraception; and pregnant or lactating women.

At time of surgery (month 0 (M0)), patients provided faecal samples before colonic cleansing. Biopsies were sampled using biopsy pinches from the fresh resected tissue at the ileal level in macroscopically ulcerated regions. Tissue specimens were also collected (4 cm² surface). Patients were examined 6 months after ICR (month 6 (M6)), provided faecal samples and an ileocolonoscopy was performed. Biopsies were sampled from the neoterminal ileum (above the anastomosis) and the subanastomotic colon (below the anastomosis). Endoscopic status was determined (recurrence of inflammatory lesions (REC); remission (REMI)). Endoscopic recurrence was defined by a Rutgeerts score ≥2. All samples were immediately dry frozen in nitrogen or dry ice and further kept at −80°C before analysis. At 1-year follow-up, endoscopic and clinical recurrence was assessed by clinicians.

**DNA preparation**

Total DNA was extracted from faeces and biopsy samples as previously described. DNA concentration and integrity were determined spectrophotometrically and bacterial 16S rRNA gene was amplified using either primers targeting the V6-V8 region (GCclamp-U968 and L1401) for fingerprinting or the V3-V4 region for sequencing (V3fwd: 5’-TAGGGAC GCAGCAG-3’, V4rev: 5’-GGACTACGTHGTTATCTAAT-3’).

**Fingerprinting of the dominant microbiota**

Sequence-specific fingerprints were obtained with Temporal Temperature Gradient Gel Electrophoresis (TTGE) as previously described. TTGE profiles were analysed with Gel Compar software V2.0 (Applied Maths, Kortrijk, Belgium). Similarity indexes (Pearson correlation method with unweighted pair group method with arithmetic mean (UPGMA) method) were calculated for each pair of profiles. Means were compared using paired Student’s t test when the variances were equal, and otherwise using Wilcoxon’s test.

**Microbial composition assessment by high-throughput sequencing**

Ten patients (ie, 46 samples: 26 mucosal samples and 20 faecal samples; see online supplementary table S1) were selected from the main cohort and their microbiota composition was further deeply analysed by 454 pyrosequencing using GS-FLX-Titanium technology following manufacturer’s instructions (Roche) for mucosal samples or MiSeq (Illumina) for faecal samples. Faecal samples from one patient provided low number of sequences and were discarded. Sequences were trimmed for adaptors and PCR primers removal and binned for a minimal sequence length of 250 bases and an average minimal base quality threshold set at 25. Resulting sequences (in average 2915 for mucosal samples and 16 532 for faecal samples) were clustered at 97% of identity using QIIME and usearch (V5.2.32) pipeline. Operational taxonomic units (OTUs) with abundance lower than four reads were discarded. Chimera detection and removal were assessed using GOLD reference database anduchime. OTUs were assigned to closest taxonomic neighbours using SEGMATCH and up to date 16S rRNA gene RDP database (release 10, update 30). Alpha diversity (Shannon index) was analysed on the OTU table rarefied to 1000 reads.

All statistical analyses were performed using R program, ade4 and igraph packages. Statistics was assessed using either a Wilcoxon’s test or the analysis of variance (p<0.05). If required, p values were adjusted for multiple testing effects using the Bonferroni correction. Principal component and between-class analyses were performed to map each sample based on their overall microbial composition and to assess similarities between individual’s microbiota. Robustness of each clustering result was assessed using a Monte Carlo rank test (p<0.05). The network analysis was carried out with SparCC (bootstrap n=500) on the most abundant OTUs (maximum abundance of a particular OTU within a sample ≥0.125%); SparCC correlation scores ≤−0.5 or ≥0.5 with a p≤0.001 were
RESULTS

Twenty patients were included in the study. Six months after surgery, 10 patients had developed recurrence of CD lesions (REC) visible during endoscopic examination while the other half remained in endoscopic remission (REM) according to the Rutgeerts score. A total of 337 OTUs was detected in mucosal samples with an average of 88±34 OTUs per sample, while 1225 OTUs constituted the faecal microbiota with an average of 327±124 OTUs per sample. Bacterial phylogenotypes (or OTUs) were defined as groups of sequences sharing at least 97% of similarity and OTUs' representative sequences were phylogenetically affiliated to their closest relative bacterial species.

ICR for CD affects the mucosal microbiota, which is also depicted in faecal samples

ICR had a striking effect on gut microbial composition. Bacterial profiles of the dominant mucosal microbiota at 6 months after ICR (M6) differed markedly from the profiles observed at time of surgery (M0). The average TTGE pairwise similarity percentages were 55.1%±25.0% between ileal mucosa at M0 and the neoterminal ileum at M6, and 48.1%±28.9% between ileal mucosa at M0 and subanastomotic colon at M6. The composition of mucosal microbiota, analysed by 16S rRNA gene pyrosequencing, was strongly affected by ICR (figure 1). Samples collected at M0 were significantly enriched in bacteria belonging to α-β-Proteobacteria and Bacilli (Streptococcus), whereas M6 samples had higher proportions of Clostridia (see online supplementary table S2 and supplementary figure S1). Lachnospiraceae family displayed the largest variation between M0 and M6 with percentages ranging from 7.39%±2.79% (M0) to 31.01%±7.82% (REC) and 27.17%±4.78% (REM). Top-down taxonomic analysis emphasised that Dorea and Blautia genera accounted mostly for this variation. Strikingly, Porphyromonadaceae levels were also increased in M6 samples, but only in patients with endoscopic recurrence. At OTU level, 27 bacterial species were differentially abundant between M0 and M6 sampling times (table 1; M0=17 OTUs and M6=10 OTUs).

At M0, the intestinal mucosa of patients with CD harboured high proportions of unusual, facultative anaerobic or aerobic gut bacteria such as Streptococcus mitis, Undibacterium oligoacarbophilum, Sphingomonas melonis and Gemella haemolysans. On the other hand, 6 months after ICR, mucosal samples exhibited higher levels of anaerobic bacteria belonging to Lachnospiraceae: Clostridium nexile, Blautia wexlerae and Dorea longicatena. Bacteroidaceae, Enterobacteriaceae and Bifidobacteriaceae were not impacted by ICR.

No difference was observed within the α-diversity between M0 and M6 samples (Shannon index, M0: 2.538±0.3179 and M6: 3.030±0.111, p>0.05).

ICR also impacted faecal bacterial populations, and the average TTGE profiles similarity percentage between M0 and M6 was 41.3%±34.1%. The inter-individual variability was high and similarity ranged from 0% to 94.9% between M0 and M6. No significant differences were noticeable depending on the endoscopic status at 6 months (remission or recurrence).

Average TTGE profiles similarity percentages were 45.1%±23.4% for patients in remission and 58.1%±30.1% for patients with endoscopic recurrence.

Towards a link between bacterial dysbiosis and postoperative recurrence

The mucosa-associated microbiota was analysed in detail by 16S rRNA gene sequencing in 10 patients: 5 having persistent endoscopic remission and 5 with recurrence. No significant difference was observed between REC and REM α-diversity (Shannon index, REC: 2.907±0.513 and REM: 3.131±0.485, p>0.05). The mucosal microbiota differed markedly between these two groups of patients. Remission status was characterised by an increased number of bacteria belonging to four genera (Bacteroides, Dorea, Ruminococcus and Dialister; see online supplementary table S3) and mainly the species D. longicatena and Bacteroides plebeus (table 2). On the other hand, Gemmiger formicilis, Enterococcus durans and Ruminococcus lactaris were significantly increased in REC patients as were bacteria belonging to Bacilli class.

All but 4 of these 14 specific species (Clostridium bolteae, Bacteroides dorei, Ruminococcus schinkii and Clostridium thermocellum) were also detected in faecal samples from the patients although at lower percentages. A similar trend in being over-represented or under-represented in remission or recurrence was observed in faeces but statistical significance was not reached. We searched for bacterial biomarkers of the clinical outcome in faecal samples of patients at M0 before surgery and detected significant differences in the bacterial composition of faecal samples at M0 between patients that appeared to stay in
remission after ICR compared with those who finally experienced endoscopic recurrence. At the OTUs level, four specific molecular species had a biomarker potential, two for remission prediction and two for recurrence prediction (figure 2A). While detection of C. catus L8 and a relative of Clostridiales bacterium DJF_B152 (Butyricicoccus genus) in faeces of patients at M0 were significantly associated with remission at M6, the presence of Proteus mirabilis and of a relative of Eubacterium rangiferina were highlighted as biomarkers of future recurrence in patients undergoing ICR (OTUs denovo1092, 326, 423 and 861, respectively). Moreover, OTU denovo1092 and denovo326 were significantly more represented at M0 in patients being in remission at M6 than in REC patients (p=0.034 and 0.044, respectively; figure 2B).

Postoperative recurrence: from microbial dysbiosis to microbiota destructuration

Unravelling interactions among different species within ecosystems is essential to understand how microbiota responds/adapts to environmental changes. Here we describe the use of SparCC correlation-based approach to infer species association (network) for the mucosal microbiota at each clinical status time points (M0, REC, REM). Species co-occurrence and exclusion are assessed at the overall ecosystem level, and groups of highly correlated OTUs are further defined as clusters. Clusters may relate to metabolic entities involved in trophic chains or immune reactions, specific bacterial features such as aggregation, signalling, biofilm formation or specific habitat characteristics (pH, mucins). Out of 387 total OTUs, only 13 made up the mucosal microbiota community structure of the patients with CD before operation (M0, see online supplementary figure S2 and supplementary table S6). Eighty-seven per cent of these OTUs (n=13) were common to the mucosal microbiota

Table 1 Differentially represented OTUs between samples collected at time 0 and 6 months after ICR

<table>
<thead>
<tr>
<th>OTUs</th>
<th>Closest species (% of sequence similarity)</th>
<th>Time 0</th>
<th>REC6</th>
<th>REM6</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>28</td>
<td>Streptococcus mitis (100%)</td>
<td>1.4±0.5</td>
<td>0.6±0.3</td>
<td>0.01±0.0</td>
<td>0.038</td>
</tr>
<tr>
<td>58</td>
<td>Undibacterium oligocarboniphilum (100%)</td>
<td>4.5±0.2</td>
<td>0.8±0.1</td>
<td>0.01±0.0</td>
<td>0.017</td>
</tr>
<tr>
<td>68</td>
<td>Sphingomonas melonis (100%)</td>
<td>1.8±0.5</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.009</td>
</tr>
<tr>
<td>64</td>
<td>Gemella haemolyctica (100%)</td>
<td>1.7±0.8</td>
<td>0.4±0.2</td>
<td>0.00±0.0</td>
<td>0.027</td>
</tr>
<tr>
<td>87</td>
<td>Clostridium lituseburensis (98%)</td>
<td>1.7±0.9</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.027</td>
</tr>
<tr>
<td>91</td>
<td>Therms scotoductus (100%)</td>
<td>1.5±0.7</td>
<td>0.3±0.4</td>
<td>0.0±0.0</td>
<td>0.028</td>
</tr>
<tr>
<td>76</td>
<td>Mesorhizobium australicum (99%)</td>
<td>1.4±0.7</td>
<td>0.1±0.0</td>
<td>0.0±0.0</td>
<td>0.009</td>
</tr>
<tr>
<td>124</td>
<td>Granulicatella adiacens (100%)</td>
<td>1.2±0.7</td>
<td>0.1±0.0</td>
<td>0.0±0.0</td>
<td>0.028</td>
</tr>
<tr>
<td>250</td>
<td>Staphylococcus warneri (100%)</td>
<td>0.7±0.4</td>
<td>0.1±0.0</td>
<td>0.0±0.0</td>
<td>0.041</td>
</tr>
<tr>
<td>142</td>
<td>Granulicatella elegans (100%)</td>
<td>0.6±0.3</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.006</td>
</tr>
<tr>
<td>227</td>
<td>Bradyrhizobium yanunmogense (100%)</td>
<td>0.5±0.2</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.007</td>
</tr>
<tr>
<td>226</td>
<td>Sediminibacterium salmoneum (96%)</td>
<td>0.4±0.2</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.01</td>
</tr>
<tr>
<td>243</td>
<td>Pseudomonas flavescens (100%)</td>
<td>0.2±0.2</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.027</td>
</tr>
<tr>
<td>256</td>
<td>Rhodospirillum rubrum (86%)</td>
<td>0.2±0.1</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.005</td>
</tr>
<tr>
<td>233</td>
<td>Turicibacter sanguinis (100%)</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.005</td>
</tr>
<tr>
<td>15</td>
<td>Eubacterium coprostagenolis (92%)</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.005</td>
</tr>
<tr>
<td>10</td>
<td>Clostridium nile (100%)</td>
<td>0.1±0.0</td>
<td>4.7±1.5</td>
<td>0.8±0.4</td>
<td>0.033</td>
</tr>
<tr>
<td>9</td>
<td>Blautia wexlerae (100%)</td>
<td>0.3±0.1</td>
<td>2.8±1.2</td>
<td>4.1±0.8</td>
<td>0.036</td>
</tr>
<tr>
<td>12</td>
<td>Dorae longicanes (100%)</td>
<td>0.4±0.2</td>
<td>0.4±0.2</td>
<td>3.1±0.7</td>
<td>0.022</td>
</tr>
<tr>
<td>53</td>
<td>Sutterella wadsworthensis (100%)</td>
<td>0.0±0.0</td>
<td>0.2±0.1</td>
<td>0.6±0.2</td>
<td>0.025</td>
</tr>
<tr>
<td>199</td>
<td>Ruminococcus shirini (97%)</td>
<td>0.0±0.0</td>
<td>0.3±0.0</td>
<td>0.2±0.1</td>
<td>0.003</td>
</tr>
<tr>
<td>288</td>
<td>Bacteroides dorei (99%)</td>
<td>0.0±0.0</td>
<td>0.3±0.0</td>
<td>1.4±0.0</td>
<td>0.035</td>
</tr>
<tr>
<td>241</td>
<td>Desulfotomaculum guttioideum (98%)</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.1±0.0</td>
<td>0.01</td>
</tr>
<tr>
<td>1</td>
<td>Bacteroides plebeius (100%)</td>
<td>0.2±0.2</td>
<td>0.0±0.0</td>
<td>2.4±0.9</td>
<td>0.029</td>
</tr>
<tr>
<td>153</td>
<td>Clostridium bistole (95%)</td>
<td>0.0±0.0</td>
<td>0.0±0.0</td>
<td>0.4±0.2</td>
<td>0.034</td>
</tr>
</tbody>
</table>

Shadeless and grey-shaded lines indicate respectively increased OTUs in samples either collected at time 0 or time 6. Statistics was assessed by analysis of variance. Only significant data (p<0.05) are presented.

ICR, ileocolonic resection; OTUs, operational taxonomic units; REC, recurrence; REM, remission.

Table 2 Differentially represented OTUs between recurrence and remission samples collected at 6 months after ICR

<table>
<thead>
<tr>
<th>OTUs</th>
<th>Closest species (% of sequence similarity)</th>
<th>REC6</th>
<th>REM6</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>20</td>
<td>Gemmern firmicilis (100%)</td>
<td>1.5±0.7</td>
<td>0.7±0.5</td>
<td>0.038</td>
</tr>
<tr>
<td>335</td>
<td>Enterococcus durans (100%)</td>
<td>0.5±0.4</td>
<td>0.0±0.0</td>
<td>0.011</td>
</tr>
<tr>
<td>78</td>
<td>Ruminococcus lactis (96%)</td>
<td>0.3±0.1</td>
<td>0.0±0.0</td>
<td>0.015</td>
</tr>
<tr>
<td>12</td>
<td>Dorae longicanes (100%)</td>
<td>0.4±0.2</td>
<td>3.1±0.7</td>
<td>0.011</td>
</tr>
<tr>
<td>1</td>
<td>Bacteroides plebeius (100%)</td>
<td>0.0±0.0</td>
<td>3.1±1.2</td>
<td>0.013</td>
</tr>
<tr>
<td>153</td>
<td>Clostridium bistole (95%)</td>
<td>0.0±0.0</td>
<td>0.4±0.2</td>
<td>0.006</td>
</tr>
<tr>
<td>101</td>
<td>Bacteroides dorei (99%)</td>
<td>0.0±0.0</td>
<td>0.4±0.1</td>
<td>0.019</td>
</tr>
<tr>
<td>208</td>
<td>Butyricimonas virosa (98%)</td>
<td>0.0±0.0</td>
<td>0.3±0.2</td>
<td>0.05</td>
</tr>
<tr>
<td>199</td>
<td>Ruminococcus shirini (97%)</td>
<td>0.0±0.0</td>
<td>0.2±0.1</td>
<td>0.005</td>
</tr>
<tr>
<td>97</td>
<td>Bilophila wadsworthii (100%)</td>
<td>0.0±0.0</td>
<td>0.1±0.1</td>
<td>0.05</td>
</tr>
<tr>
<td>237</td>
<td>Bacteroides coprocola (100%)</td>
<td>0.0±0.0</td>
<td>0.1±0.1</td>
<td>0.013</td>
</tr>
<tr>
<td>241</td>
<td>Desulfotomaculum guttioideum (98%)</td>
<td>0.0±0.0</td>
<td>0.1±0.0</td>
<td>0.013</td>
</tr>
<tr>
<td>312</td>
<td>Bacteroides nordii (100%)</td>
<td>0.0±0.0</td>
<td>0.1±0.1</td>
<td>0.028</td>
</tr>
<tr>
<td>62</td>
<td>Clostridium thermodendrum (88%)</td>
<td>0.0±0.0</td>
<td>0.1±0.0</td>
<td>0.021</td>
</tr>
</tbody>
</table>

Shadeless and grey-shaded lines indicate respectively increased OTUs in patients with disease recurrence or remission. Statistics was assessed by Wilcoxon test. Only significant data (p<0.05) are presented.

ICR, ileocolonic resection; OTUs, operational taxonomic units; REC, recurrence; REM, remission.
structure inferred for the patients 6 months after ICR (see online supplementary figure S3). Within the M0 structure, no distinct and significant bacterial cluster was identified.

The mucosal microbiota structure of patients in remission after 6 months (REM) was more complex and better organised than the structure inferred for patients suffering from disease recurrence (REC) (figure 3). The REM microbiota structure was composed of 192 OTUs, whereas 102 OTUs were found in the REC structure (see online supplementary tables S4 and S5, respectively) with 82 OTUs common to both structures. The number of inter-OTUs correlations was five times higher for REM microbiota (2142) compared with REC one (436). Both REM and REC network structures were made up of five significant clusters. Each microbial cluster was well distributed in the cohort of patients, either patients in remission (see online supplementary figure S4A) or with recurrence (see online supplementary figure S4B).

Among the five REM microbial clusters, clusters I, III and IV were made up of bacteria mainly related to Firmicutes phylum (70%, 67% and 63%, respectively). Main species in cluster I

---

**Figure 2** Early bacterial biomarkers of the clinical outcome after ileocolonic resection (ICR). Faecal microbiota from 10 patients was analysed at M0 and 6 months after ICR. (A) Specific bacterial operational taxonomic units (OTUs) that may predict at M0 the clinical outcome following ICR were deciphered applying the LEfSe algorithm.47 The LEfSe algorithm uses the non-parametric factorial Kruskal–Wallis sum-rank test to detect features with significant differential abundance with respect to the clinical outcome; biological significance is subsequently investigated using a set of pairwise tests using the (unpaired) Wilcoxon rank-sum test. As a last step, LEfSe uses linear discriminant analysis to estimate the effect size of each differentially abundant feature (ie, bacterial OTUs). (B) Boxplot of the distribution (per cent of total reads) of the four OTUs highlighted in the LEfSe analyses in the different patients’ groups. M0 bacterial biomarkers associated with remission at M6 are in green. M0 bacterial biomarkers of future recurrence in patients undergoing ICR are in red. M0, samples at time of surgery; REC, recurrence; REM, remission; LDA, linear discriminant analysis.
related to Faecalibacterium prausnitzii, Ruminococcus bromii and B. plebeius, whereas G. formicilis was the main driver of cluster III. Interestingly, cluster I represented a tight community, mainly constituted with OTUs from the Ruminococcaceae and Lachnospiraceae families, with each OTU sharing in average 16.45 correlations with other OTUs of the cluster. The cluster

![Correlation network organisation inferred from the microbiota composition of patients with Crohn’s disease in remission and in recurrence 6 months after ileocolonic resection (ICR).](image)

**Figure 3** Correlation network organisation inferred from the microbiota composition of patients with Crohn’s disease in remission and in recurrence 6 months after ileocolonic resection (ICR). (A) and (B) respectively depict the correlation network structures inferred from the microbiota composition of patients in remission or with recurrence 6 months after ICR. Each number relates to operational taxonomic unit (OTU) indexes. OTU phyla are at phylum level is described by colours filling each OTU dot. Correlation scores are indicated by the colour of the edges linking OTU pairs. Polygons delineate each cluster (C1–C5) identified in the network. (A and B) The red, yellow, green, blue and purple polygons delineate clusters I, II, III, IV and V.

II was taxonomically more diverse and composed of Firmicutes (49%), Bacteroidetes (34%) and Proteobacteria (11%) phyla. The most abundant OTUs related to Dorea formicigenerans, Sutterella wadsworthensis and Bacteroides uniformis. Finally, cluster V grouped OTUs affiliated to Firmicutes (42%), Proteobacteria (31%), Bacteroidetes (15%) and Actinobacteria (8%). Firmicutes population showed balanced proportions of Clostridia and Bacteroides classes with OTUs related to Clostridium, Blautia, Streptococcus, Gemella and Granulicatella genera (as opposed to Clostridia class alone in cluster I).

On the other hand, the REC microbiota structure included five different clusters that were looser than in the REM microbiota structure (average 4.27 correlations/OTUs in REC vs 11.16 correlations/OTUs in REM). The cluster II was composed at 50% with Proteobacteria (α/β-Proteobacteria) and OTUs were affiliated to Comamonas and Pelomonas genera. The cluster III grouped Clostridium hylemonae, Ruminococcus gnavus and E. durans, a group of species specifically involved in bile acids (BAs) hydroxylation and bile salts hydrolysis. E. prausnitzii was only detected once in cluster III, and out of five correlations shared by E. prausnitzii within this cluster, four were negative. Similarly to the microbiota of patients in remission, two clusters enriched in Firmicutes were detected, one mainly containing Clostridia (cluster IV) and the other Bacteroides (cluster I). Finally, the cluster V, driven mainly by Bacteroides caccae and Eubacterium hallii, grouped bacteria that were well distributed in terms of phyla repartition.

Colonisation of the neoterminal ileum and subanastomotic colon after ICR

Comparison between the microbiota colonising the neoterminal ileum and the subanastomotic mucosa highlighted an average TTGE profile similarity percentage of 82.6%±21.8%. Interestingly, dominant mucosal microbiota in the neoterminal ileum and subanastomotic colon were significantly closer within the patients in remission at M6 than in patients with recurrence (REM: 92.2±2.7; REC: 77.9%±24.7; p=0.02). A similar trend was observed with the pyrosequencing analysis (figure 4). Species from Dorea and Brevundimonas accounted for those explaining this difference. D. longicatena (REC-sub: 0.265±0.247 and REC-sus: 0.636±0.314) and Brevundimonas vesicularis (REC-sub: 0.022±0.022 and REC-sus: 0.203±0.096) were respectively 2.4-fold and 9.2-fold increased in the neoterminal ileum mucosa compared with the subanastomotic one in patients with recurrence.

DISCUSSION

At time of surgery, the mucosal microbiota of patients with active CD was rich in α/β-Proteobacteria, Bacteroides and more largely in bacteria that are not usually found in a healthy gut microbiota. This is in line with previous studies.

While not affecting the gut microbial diversity, ICR markedly modified the gut mucosal microbiota. Following ICR, a fourfold increase of Lachnospiraceae taxa was observed showing deep modifications within the gut ecosystem. Lachnospiraceae abundance has previously been noticed to fluctuate at both faecal and mucosal levels in patients with CD with active disease. ICR also led to an increase in Porphyromonadaceae levels in patients with endoscopic recurrence at 6 months, and this was also observed in the jejunal mucosa of a mouse model of resection.

It is noteworthy that microbial assemblage and recolonisation process after ICR were associated to disease relapse or maintenance of remission. Indeed, mucosal microbiota comparison of patients being either on disease remission or recurrence 6 months after ICR has shed light on different gut ecosystem composition and structures. Our results suggest that recovering an eubiotic microbiota, mainly composed of Firmicutes and Bacteroidetes, is a crucial step towards remission in patients with CD after resection. Moreover, homogeneity in bacterial composition at the anastomosis location might be associated with homeostasis and remission in these patients. Compositional differences mainly related to an increase in Bacteroides abundance during disease recurrence, whereas bacteria belonging to Bacteroides, Dorea, Ruminococcus and Dialister genera were more prevalent in patients in remission. We also assessed whether specific bacterial biomarkers in faecal samples may predict, at the time of surgery, the clinical outcome of patients after ICR. Two OTUs, both being relatives of butyrate-producing bacteria (ie, C. catus and Butyrivibrio sp.), were more abundant in M0 faecal samples of patients being in remission at 6 months and undetectable at M0 in the microbiota of patients with endoscopic recurrence at M6. On the other hand, two OTUs were specific predictors of recurrence following ICR: E. tannigera and P. mirabilis. It is noteworthy that P. mirabilis has been shown to be able to promote colitis in susceptible animals, but also to induce robust interleukin-1b secretion via the NLRP3 inflammasome, hence promoting inflammation.

In order to study the structure and thus the interactions among the bacterial components of mucosal microbiota, we built a correlation network based on the relative abundance of OTUs among the different samples. The gut microbiota structure differed significantly whether patients’ disease evolved towards maintenance of remission or recurrence of lesions. A major result is the identification of a complex mucosal ecosystem made of gut commensals and associated with disease remission. At the opposite, the microbiota structure of patients...
displaying CD recurrence appeared less organised. In a recent study, Levy and Borenstein applied systems biology and metabolomic modelling to highlight forces driving species composition in the gut microbiome. This metabolic-based prediction of species interaction showed that habitat is the dominant structuring force of the human microbiome. Here we show that CD activity is associated with a loose and non-cohesive mucosal microbiota structure that might impair proper ecosystem functions. On the other hand, a tightly correlated and cohesive species structure was observed in patients in remission 6 months after ICR.

Whatever the clinical status of patients 6 months after ICR, we observed at least one cluster containing mostly bacteria belonging both to the phylogenetic and the metagenomic core (REM: cluster II and III; REC: cluster V). These clusters may constitute a functional core required for the performance of the gut ecosystem. The microbial community structure of patients in remission also presented a cluster mainly driven by F. prausnitzii and R. bromii. Both species are thought to play a beneficial role in human health, partly through the production of short-chain fatty acids (SCFAs; butyrate mostly) and were more abundant in healthy subjects than in patients with CD. Moreover, F. prausnitzii has been associated with clinical benefit in CD and its anti-inflammatory properties have been demonstrated in animal models. R. bromii is a strong degrader of resistant starches and proved to be unique in stimulating starch utilisation by other bacterial species, which may enhance the production of SCFAs in this cluster. On the other hand, the microbial structure of patients with recurrence 6 months after ICR exhibited a cluster enriched in Proteobacteria (α- and β-Proteobacteria) and composed of unusual bacteria that were also detected in the mucosa of patients with IBD in several previous studies. Interestingly, another community (cluster III) specific of REC patients was composed of bacteria sharing specific enzymatic machinery associated with the metabolism of BAs. Hence, E. durans, a component of this cluster, exhibits bile salt hydrolase activity and may deconjugate BAs. Moreover, C. bilelmonae and R. gnavus, main contributors of this cluster, both possess a high BA 7α-dehydroxylation activity, leading to the production of secondary BAs. Of note, high concentrations of secondary BAs in faeces have been linked to the pathogenesis of colon cancer and more recently to CD, and several studies also reported increased R. gnavus proportions in the mucosa and in faeces of patients with CD.

Ecological forces and key bacterial species that support these mucosal microbial communities still remain to be determined. Yet the presented global approach may allow a better understanding of microbial modulation by environmental factors (diet, prebiotics, antibiotics, pH, oxygen) but mostly pave the way towards general microbiota ecosystem modulation on the gut by regulating specific bacteria in the structure.

CONCLUSION
We highlighted specific bacteria, with either increased or decreased proportions, associated with early recurrence of CD inflammatory lesions. Moreover, we applied robust statistical analysis to assess the structure (bacterial phyotypes clusters and correlation networks) of the mucosa-associated microbial ecosystem in these patients and highlighted an overall ecosystem disruption in patients with CD recurrence after ICR.

Looking at the level of ecosystem structure may be a critical step in the development of therapeutic interventions targeting the microbiota in CD, including antibiotics and/or faecal transplantation.

Author affiliations
1 INRA, Micalis UMR1319, Jouy-en-Josas, France
2 AgroParisTech, Micalis UMR1319, Jouy-en-Josas, France
3 Institut Curie, U932, Paris, France
4 Sorbonne Université—UPMC Univ Paris 06, INSERM U1157, AP-HP, Hôpital Saint-Antoine, CNRS UMR 7203 LBM, CHU Saint-Antoine, Paris, France
5 Gastroenterology Department, Hôpital Saint Louis, APHP, INSERM U1160, Université Paris 7, GETAID, Paris, France
6 Gastroenterology Department, Hôpital Beaujon, Clichy, Université Paris 7, GETAID, Paris, France
7 Department of Gastroenterology, Icahn School of Medicine, New York, New York, USA
8 EA Laboratoire de Biologie, Conservatoire national des arts et métiers, Paris, France
9 EA4065 Université Paris V, Paris, France
10 Gastroenterology Department, Hôpital Lariboisière & Université Denis Diderot—Paris 7, Sorbonne Paris Cité & GETAID, Paris, France
11 GETAID, Groupe d’Etude des Traitements des Affections Inflammatoires Digestives, Paris, France

Acknowledgements
The authors thank the GETAID, Eduardo Schiffin and Stephanie Blum for critical construction of the clinical study design; Anne Berger, Pierre Cattan, Simon Msika and Yves Paris for providing rapid access to the surgical specimen, Karine Le Roux and Céline Monot for technical support and Nestlé Research for sponsorship.

Contributors
SM and PL contributed equally. PL, PS, PP, JD and PM designed the research. All authors contributed to data acquisition, analysis and results interpretation. SM, PL and PM wrote the manuscript. All authors revised and approved the manuscript.

Competing interests
None declared.

Ethics approval
HEGP-Broussais Ethics Committee.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data sharing statement
All data are fully available without restriction. All relevant data are within the paper and its supporting information files. DNA sequence reads from this study are available from the Sequence Read Archive (accession numbers available after acceptance) or by contacting the corresponding author.

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES


Copyright © 2015 Gut. Published by BMJ Publishing Group Ltd. All rights reserved. For permission to reuse any of this content visit http://group.bmj.com/group/rights-licensing/permissions

For permissions to make commercial use of this article or image, please visit http://group.bmj.com/group/rights-licensing/permissions

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Gut microbiota

Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery

S Monodot, P Lepage, P Seksik, M Allez, X Tréton, Y Bouhnik, J F Colombel, M Leclerc, P Pochart, J Doré, P Marteau and the GETAID

Gut published online December 1, 2015

Updated information and services can be found at:
http://gut.bmj.com/content/early/2015/12/01/gutjnl-2015-309184

These include:

Supplementary Material
Supplementary material can be found at:
http://gut.bmj.com/content/suppl/2015/12/01/gutjnl-2015-309184.DC1

References
This article cites 45 articles, 15 of which you can access for free at:
http://gut.bmj.com/content/early/2015/12/01/gutjnl-2015-309184#BIBL

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Open access (354)
Crohn's disease (932)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/